Allspring Global Investments Holdings LLC Invests $244,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Allspring Global Investments Holdings LLC acquired a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,180 shares of the specialty pharmaceutical company's stock, valued at approximately $244,000.

A number of other institutional investors have also made changes to their positions in COLL. Invesco Ltd. raised its position in Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after acquiring an additional 289,335 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after purchasing an additional 5,480 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Collegium Pharmaceutical by 5.6% in the fourth quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock valued at $11,035,000 after purchasing an additional 20,490 shares during the last quarter. Royce & Associates LP increased its holdings in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after purchasing an additional 33,674 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after purchasing an additional 221,903 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded down $0.48 during trading hours on Friday, reaching $32.52. 189,895 shares of the stock were exchanged, compared to its average volume of 399,671. The stock has a 50 day moving average of $29.70 and a two-hundred day moving average of $29.60. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a current ratio of 1.08, a quick ratio of 1.01 and a debt-to-equity ratio of 3.30. The company has a market cap of $1.04 billion, a P/E ratio of 26.66 and a beta of 0.64.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The company's revenue for the quarter was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.45 earnings per share. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical announced that its board has authorized a share repurchase plan on Monday, July 7th that permits the company to buyback $150.00 million in shares. This buyback authorization permits the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.

Insider Transactions at Collegium Pharmaceutical

In related news, Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the completion of the transaction, the director owned 70,658 shares in the company, valued at $2,163,547.96. This trade represents a 8.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.51% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Piper Sandler reiterated a "neutral" rating and issued a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $43.75.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.